782475-32-5

Upstream product

• 123-54-6 acetylacetone 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 192650-25-2 6-(4-nitrophenyl)hexane-2,4-dione 
• 782475-33-6 C₁₆H₂₁NO₆ 

Downstream Products

• 929087-94-5 3-[2-(2-{2-[2-(2-{2-[2-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenylcarbamoyl)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-propionic acid 
• 909008-17-9 C₃₀H₄₇NO₁₂ 
• 929088-03-9 3-[4-(2-{2-[2-(2-{2-[4-(3,5-dioxo-hexyl)-phenylcarbamoyl]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-phenyl]-N-[2'-(isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-N-methyl-propionamide 
• 929088-02-8 N-[4-(3,5-dioxo-hexyl)-phenyl]-3-{2-[2-(2-{2-[4-({[2'-(isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-methyl-carbamoyl}-methyl)-phenoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-propionamide 
• 929087-93-4 N-(2'-(isoxazol-5-ylsulfamoyl)-4-{2-[2-(2-{2-[2-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenylcarbamoyl)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-biphenyl-2-ylmethyl)-3,3,N-trimethyl-butyramide 
• 929087-81-0 N-[4-(2-{2-[2-(2-{2-[4-(3,5-dioxo-hexyl)-phenylcarbamoyl]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-2'-(isoxazol-5-ylsulfamoyl)-biphenyl-2-ylmethyl]-3,3,N-trimethyl-butyramide 
• 929087-80-9 N-[4-(3,5-dioxo-hexyl)-phenyl]-3-(2-{2-[2-({[2'-(isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-methyl-carbamoyl}-methoxy)-ethoxy]-ethoxy}-ethoxy)-propionamide 
• 929088-01-7 3-(4-{2-[2-(2-{2-[2-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenylcarbamoyl)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-phenyl)-propionic acid 
• 929088-00-6 (4-{2-[2-(2-{2-[2-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenylcarbamoyl)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-phenyl)-acetic acid 
• 929087-89-8 3-(2-{2-[2-({[2'-(isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-methyl-carbamoyl}-methoxy)-ethoxy]-ethoxy}-ethoxy)-N-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenyl)-propionamide 
• 929087-92-3 3-{2-[2-(2-{2-[2-formyl-2'-(isoxazol-5-ylsulfamoyl)-biphenyl-4-yloxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-N-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenyl)-propionamide 

Relevant academic research and scientific papers

ANTI-ANGIOGENIC COMPOUNDS

The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.

Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodies

Aryl sulfonamide-based endothelin antagonists were synthesized and covalently linked to the reactive lysine of the m38C2 antibody to create a series of CovX-Bodies. These chemically programmed antibodies behaved as potent endothelin receptor antagonists in vitro and had antitumor efficacy in a prostate cancer xenograft model which, on a molar basis, far exceeded the activity of the parent small molecule.

Anti-angiogenic compounds

The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.